Research location
Tomaszów Mazowiecki
Poland
Advertisement
Research activity in Tomaszów Mazowiecki
PolandCureCurrent currently publishes aggregate city-level research activity for this location: 25 trials and 25 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Tomaszów Mazowiecki
25 linked trials · page 1 of 1RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveNCT07413939 · 2026-05-21 · 1 site observation
RECRUITING
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280 · 2025-09-29 · 1 site observation
RECRUITING
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)NCT07111520 · 2025-09-22 · 1 site observation
RECRUITING
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical PracticeNCT07284121 · 2025-07-15 · 1 site observation
RECRUITING
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerNCT06203210 · 2024-05-21 · 1 site observation
RECRUITING
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCNCT04686305 · 2021-03-09 · 1 site observation
RECRUITING
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)NCT06920771 · 2024-09-09 · 1 site observation
COMPLETED
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)NCT05153239 · 2022-07-22 · 1 site observation
COMPLETED
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerNCT05221840 · 2022-02-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data SettingNCT05478590 · 2021-11-22 · 1 site observation
COMPLETED
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)NCT05104866 · 2021-10-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)NCT04964934 · 2021-06-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.NCT04642469 · 2020-11-30 · 1 site observation
COMPLETED
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)NCT04385368 · 2020-07-17 · 1 site observation
COMPLETED
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast CancerNCT03937154 · 2020-02-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurgeryNCT04026412 · 2019-10-08 · 1 site observation
COMPLETED
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBCNCT03997123 · 2019-06-25 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin BeforeNCT03951805 · 2019-05-09 · 1 site observation
COMPLETED
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and DiagnosticsNCT04136470 · 2019-04-01 · 1 site observation
UNKNOWN
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCNCT03819465 · 2018-12-27 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer PatientsNCT03706690 · 2018-11-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation TherapyNCT03703297 · 2018-09-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).NCT03164616 · 2017-06-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Dose Finding Study for Depigoid Birch: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-AsthmaNCT01144429 · 2010-06-01 · 1 site observation
COMPLETED
Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)NCT01078545 · 2008-09-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.